HUTCHMED (China) Ltd
HCM17.040USD
-0.410-2.35%
收盘 09/19, 16:00（美东）报价延迟15分钟
14.86B总市值
--市盈率 TTM
关于 HUTCHMED (China) Ltd 公司
和黄医药（中国）有限公司是一家主要从事药品生产及销售的投资控股公司。公司通过两个分部经营业务。肿瘤免疫学分部从事用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法的发现、开发和商业化。其中，研发（R&D）包括涵盖药物发现、开发、制造和监管职能的研发活动、内部开发药物的对外授权以及支持研发运营的行政活动，营销产品包括研发活动开发的药物的发票销售、营销、制造和分销。其他业务分部从事其他商业业务，包括其他处方药和保健产品的销售、营销、制造和分销。
公司简介
公司代码HCM
公司名称HUTCHMED (China) Ltd
上市日期May 19, 2006
CEODr. Weiguo Su, Ph.D.
员工数量1811
证券类型Ordinary Share
年结日May 19
公司地址48th Floor, Cheung Kong Center, 2 Queen's Road Central
城市
上市交易所Hochiminh Stock Exchange
国家Hong Kong
邮编- -
电话85221281188
网址https://www.hutch-med.com/
公司代码HCM
上市日期May 19, 2006
CEODr. Weiguo Su, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2023
FY2022
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月18日 周一
更新时间: 8月18日 周一
持股股东
股东类型
持股股东
持股股东
占比
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
其他
97.65%
持股股东
持股股东
占比
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
其他
97.65%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
2.38%
Investment Advisor
0.70%
Research Firm
0.30%
Hedge Fund
0.24%
Individual Investor
0.12%
Sovereign Wealth Fund
0.01%
其他
96.25%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
2023Q1
364
26.52M
15.33%
-22.52M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Schroder Investment Management (Singapore) Ltd.
1.87M
1.07%
+570.74K
+43.88%
Mar 31, 2025
Allianz Global Investors Asia Pacific Limited
945.74K
0.54%
-117.52K
-11.05%
Mar 31, 2025
Schroder Investment Management (Hong Kong) Ltd.
972.00K
0.56%
-496.17K
-33.80%
Mar 31, 2025
State Street Global Advisors (US)
336.87K
0.19%
-10.74K
-3.09%
Mar 31, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
93.92K
0.05%
+7.34K
+8.48%
Mar 31, 2025
M&G Investment Management Ltd.
258.69K
0.15%
-7.09K
-2.67%
Mar 31, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Jane Street Capital, L.L.C.
222.24K
0.13%
+124.77K
+128.01%
Mar 31, 2025
Amundi Asset Management, SAS
157.43K
0.09%
-12.82K
-7.53%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
